
|Articles|July 7, 2003
Second biologic launched for those with A1PI deficiency
Patients with a hereditary form of emphysema caused by alpha-1 proteinase inhibitor (A1PI) deficiency now have another therapeutic option. The FDA recently approved alpha1-proteinase inhibitor (human) [Aralast, Baxter] for chronic augmentation therapy in patients having congenital deficiency of A1PI with clinically evident emphysema. Aralast is currently available exclusively through the specialty pharmacy providers Accredo Health, Caremark, and Coram Healthcare. To obtain more information about Aralast, contact Baxter at (800) 423-2090.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
2
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
3
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
4
Zepbound Lowers Health Care Costs in Older Adults With Obesity
5






































